PADI-Dependent Mitochondrial Adaptation Drives Resistance to KRAS Inhibitors

◇ RESEARCH

Researchers identified PADI1 and PADI3 as negative prognostic markers in KRAS-mutant colorectal and pancreatic cancers; pharmacological inhibition of PADIs synergizes with KRAS inhibitors in preclinical models and restores sensitivity in resistant cells. (Cell Rep)